Relationship Between Left Ventricular Ejection Fraction and ICD-10 Codes Among Patients Hospitalized With Heart

Ty J Gluckman1, Shih-Ting Chiu1, Deanna Rider2

  • 1Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence Health System, Portland, Oregon, USA.

Clinical Cardiology
|December 17, 2024
PubMed

Insights

Left ventricular ejection fraction (LVEF) distribution varies by heart failure (HF) type. While systolic HF patients typically have low LVEF, diastolic HF patients often have preserved LVEF, highlighting classification nuances.

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Clinical Informatics

Background:

  • Left ventricular ejection fraction (LVEF) is crucial for classifying heart failure (HF).
  • Limited data exists on LVEF distribution across different HF classifications based on ICD-10 codes.
  • Understanding this distribution is vital for accurate patient stratification and management.

Purpose of the Study:

  • To analyze the distribution of LVEF in hospitalized heart failure patients.
  • To correlate LVEF with specific International Classification of Disease (ICD)-10 codes for heart failure types.
  • To assess the concordance between ICD-10 defined HF types and measured LVEF.

Main Methods:

  • Retrospective cross-sectional analysis of 61,238 HF hospitalizations from January 2018 to October 2022.
  • Included patients with principal HF diagnosis using specific ICD-10 codes (systolic, diastolic, combined, hypertensive heart disease).
  • Analyzed LVEF data from echocardiography within 3 months prior to hospitalization for 49,772 patients.

Main Results:

  • High concordance observed between LVEF and ICD-10 codes for systolic HF (LVEF ≤ 40%) and diastolic HF (LVEF ≥ 50%).
  • Systolic HF: 86.2% had LVEF ≤ 40%; Diastolic HF: 94.0% had LVEF ≥ 50%.
  • Hypertensive heart disease with HF and CKD showed a wider range of LVEF values.

Conclusions:

  • ICD-10 codes show good concordance with LVEF for distinct HF types (systolic, diastolic, combined).
  • However, these specific HF codes represent a small fraction (~10%) of total HF hospitalizations.
  • Further research is needed to understand LVEF distribution in broader HF populations.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
516
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
315
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
339
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382